Conditions

Ovarian Cancer

Fallopian Tube Cancer

Primary Peritoneal Cancer

Purpose of the study

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment. NCT06824467     

Official Title

TROFUSE-022/ ENGOT-ov84/ GOG-3103: Phase 3, Open-label study of MK2870 maintenance after SoC platinum-based chemotherapy +/- bevacizumab in 2L BRCAm and BRCAwt Platinum Sensitive Recurrent Ovarian Cancer. 

Who is eligible to participate?

• Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. 

• Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line and a total of 6 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC). 

• Has platinum-sensitive epithelial OC, 

• Has provided tissue of a tumor lesion that was not previously irradiated 

• Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy 

• Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Part 1) or randomization (Part 2) 

• Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening 

• Has an ECOG performance status of 0 to 1 assessed within 7 days before allocation (Part 1) or randomization (Part 2) 

Register your interest

To register your interest or find out more information about this clinical trial, please email: enquiries@gallipoliresearch.org.au. 

Study location

Gallipoli Medical Research, Greenslopes Private Hospital, Brisbane